Reata Announces Improvements in Kidney Function With Bardoxolone Methyl Maintained for Two Years

Reata Pharmaceuticals (Nasdaq:RETA) a clinical-stage biopharmaceutical company, today announced results from the long-term follow up portion of the LARIAT study demonstrating that pulmonary arterial hypertension (PAH) patients treated with bardoxolone methyl (bardoxolone) experienced kidney function improvements that were durable for two years and not associated with adverse outcomes.

As quoted in the press release:

“Loss of kidney function is common in PAH patients and associated with an increased risk of adverse outcomes and death.  Treatments for PAH improve symptoms but often worsen kidney function, placing patients at greater risk,” said Daniel W. Coyne, M.D., Nephrologist and Professor of Medicine at Washington University in St. Louis, Missouri.  “The two-year trial data are the longest available with bardoxolone and suggest raising kidney function with bardoxolone is not harmful and is likely to be beneficial in PAH patients and other disease states.”

Click here to read the full press release.